Skip to content

Fluorescent Leukocytes as a Marker of Early Sepsis/Severity

NEUTROPHIL FLUORESCENCE AS AN EARLY BIOMARKER OF SEPSIS SEVERITY IN THE EMERGENCY DEPARTMENT

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07585942
Acronym
FLAMES
Enrollment
492
Registered
2026-05-14
Start date
2026-05-12
Completion date
2027-12-12
Last updated
2026-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Disseminated Intravascular Coagulation (DIC), Sepsis, Septic Shock

Brief summary

Sepsis is a medical emergency whose prognosis depends on the early identification of patients at risk of septic shock, but the tools available in the Emergency Department remain insufficient. Neutrophils, key players in immunothrombosis, show alterations detectable via cell fluorescence (e.g., NE-SFL), which are strongly correlated with the severity of sepsis and septic DIC. The FLAMES study will evaluate, from the time of admission to the Emergency Department, the relevance of neutrophil fluorescence as an early biomarker of severity, either alone or integrated into an AI model based on the multiparametric data from the SthemA 801, with comparison to the Sysmex XN. It aims to address an unmet clinical need: the immediate stratification of the risk of severe forms of sepsis. Hypothesis: higher initial fluorescence will identify patients at risk of organ failure, septic shock, or DIC.

Interventions

None listed

Sponsors

University Hospital, Strasbourg, France
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥ 18 years * Admission to the ED * Suspected or proven infection defined by the prescription of antibiotic therapy within 24 hours following admission to the ED * Collection of an EDTA blood sample as part of routine care * Patient informed and has not expressed opposition

Exclusion criteria

* Pregnancy or breastfeeding * Legal protection measure (guardianship, curatorship, judicial protection)

Design outcomes

Primary

MeasureTime frameDescription
Evaluate the association between neutrophil fluorescence, whether isolated or integrated into an AI model based on CBC results combined with the advanced multiparametric capabilities of the SthemA 801 analyzer3 daysThe primary evaluation criterion is the occurrence of sepsis or septic shock within 72 hours following admission to the Emergency Department, defined according to SEPSIS-3 by at least one of the following: * Admission to intensive care, critical care, or continuous care * One or more acute organ failures, defined by a SOFA score ≥ 2 points * Need for vasopressor treatment * Blood lactate \> 2 mmol/L * Death within 72 hours

Countries

France

Contacts

CONTACTJulie HELMS, Professor
julie.helms@chru-strasbourg.fr+33 3 69 55 13 69

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: May 15, 2026